Continuous anifrolumab exposure safe, produces sustained SLE disease activity improvement
In the treatment of patients with systemic lupus erythematosus (SLE), long-term use of the type I interferon inhibitor anifrolumab leads to sustained improvements in disease activity, quality of life, and serologic measures, according to the results of the open-label extension study.
